Neupulse is a University of Nottingham spin-out focused on bringing to market a non-invasive wristband that eases motor and vocal tics associated with Tourette’s syndrome. The device delivers targeted stimulation intended to provide a drug-free alternative to medication and behavioural therapy, addressing a significant unmet clinical need that affects up to 2 % of children worldwide. Recent funding allows the company to progress product development, build its regulatory dossier and expand clinical evidence in preparation for launch. Management plans a mid-2026 commercial debut in the UK before scaling internationally. The £3 m raised follows a £500 k investment from the Midlands Engine Investment Fund II in 2024, giving the team additional runway for trials and early commercialisation activities. Investors highlight the technology’s global impact potential and the strong research pedigree underpinning the product.

Total raised

$8M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2026